全文获取类型
收费全文 | 168篇 |
免费 | 6篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 3篇 |
妇产科学 | 2篇 |
基础医学 | 31篇 |
口腔科学 | 2篇 |
临床医学 | 9篇 |
内科学 | 24篇 |
皮肤病学 | 3篇 |
神经病学 | 6篇 |
特种医学 | 4篇 |
外科学 | 11篇 |
综合类 | 4篇 |
预防医学 | 2篇 |
眼科学 | 1篇 |
药学 | 28篇 |
肿瘤学 | 45篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 5篇 |
2020年 | 9篇 |
2019年 | 8篇 |
2018年 | 4篇 |
2017年 | 6篇 |
2016年 | 3篇 |
2015年 | 8篇 |
2014年 | 10篇 |
2013年 | 20篇 |
2012年 | 7篇 |
2011年 | 21篇 |
2010年 | 12篇 |
2009年 | 7篇 |
2008年 | 19篇 |
2007年 | 13篇 |
2006年 | 2篇 |
2005年 | 8篇 |
2004年 | 2篇 |
2003年 | 2篇 |
2002年 | 1篇 |
2001年 | 1篇 |
1998年 | 1篇 |
1991年 | 1篇 |
排序方式: 共有175条查询结果,搜索用时 15 毫秒
1.
目的:探讨血小板源性生长因子受体(PDGFR)的表达与肾细胞癌之间的关系。方法:应用免疫组化SP法检测12例正常肾、14癌旁组织、46例肾细胞癌组织中PDGFR的表达,并结合肾癌的分级、分期和随访结果进行研究。结果:PDGFR表达于细胞膜、细胞浆和核膜;肾癌组织表达阳性率为73.91%,明显高于正常组织及癌旁组织,统计学有显著性差异(P<0.05);PDGFR的表达在肾癌的分级中有显著性差异(P<0.05),而在分期中无显著性差异(P>0.05),与肾癌5年生存率无相关关系(P>0.05)。结论:PDGFR的过度表达与肾癌的发生密切相关;PDGFR的表达未能作为肾癌生物学行为指标。 相似文献
2.
Imatinib accelerates progenitor cell‐mediated liver regeneration in choline‐deficient ethionine‐supplemented diet‐fed mice 下载免费PDF全文
András Rókusz Edina Bugyik Vanessza Szabó Armanda Szücs Sándor Paku Péter Nagy Katalin Dezső 《International journal of experimental pathology》2016,97(5):389-396
Severe chronic hepatic injury can induce complex reparative processes. Ductular reaction and the appearance of small hepatocytes are standard components of this response, which is thought to have both adverse (e.g. fibrosis, carcinogenesis) and beneficial (regeneration) consequences. This complex tissue reaction is regulated by orchestrated cytokine action. We have investigated the influence of the tyrosine kinase inhibitor imatinib on a regenerative process. Ductular reaction was induced in mice by the widely used choline‐deficient ethionine‐supplemented diet (CDE). Test animals were treated daily with imatinib. After 6 weeks of treatment, imatinib successfully reduced the extent of ductular reaction and fibrosis in the CDE model. Furthermore, the number of small hepatocytes increased, and these cells had high proliferative activity, were positive for hepatocyte nuclear factor 4 and expressed high levels of albumin and peroxisome proliferator‐activated receptor alpha. The overall functional zonality of the hepatic parenchyma (cytochrome P450 2E1 and glucose 6 phosphatase activity; endogenous biotin content) was maintained. The expression of platelet‐derived growth factor receptor beta, which is the major target of imatinib, was downregulated. The anti‐fibrotic activity of imatinib has already been reported in several experimental models. Additionally, in the CDE model imatinib was able to enhance regeneration and preserve the functional arrangement of hepatic lobules. These results suggest that imatinib might promote the recovery of the liver following parenchymal injury through the inhibition of platelet‐derived growth factor receptor beta. 相似文献
3.
Giuseppe Curigliano Xavier Pivot Javer Cortés Anthony Elias Rossano Cesari Reza Khosravan Mary Collier Xin Huang Patricia E. Cataruozolo Kenneth A. Kern Aron Goldhirsch 《Breast (Edinburgh, Scotland)》2013,22(5):650-656
PurposeThis randomized, open-label phase II study compared the efficacy of sunitinib monotherapy with that of single-agent standard-of-care (SOC) chemotherapy in patients with previously treated advanced triple-negative breast cancer (TNBC).MethodsPatients with advanced TNBC, relapsed after anthracycline- and taxane-based chemotherapy, were randomized to receive either sunitinib (37.5 mg/day) or the investigator's choice of SOC therapy. Progression-free survival was the primary endpoint.ResultsMedian progression-free survival was 2.0 months with sunitinib and 2.7 months with SOC chemotherapy (one-sided P = 0.888). Median overall survival was not prolonged with sunitinib (9.4 months) compared with SOC chemotherapy (10.5 months; one-sided P = 0.839). The objective response rate was 3% with sunitinib and 7% with SOC chemotherapy (one-sided P = 0.962).ConclusionsSunitinib monotherapy did not improve efficacy compared with SOC chemotherapy in patients with previously treated advanced TNBC, for which identification of effective treatments and therapeutic targets remains an urgent need.Trial registrationNCT00246571. 相似文献
4.
Sofia Grade Liliana Bernardino João O. Malva 《International journal of developmental neuroscience》2013
Mobilization of remyelinating cells spontaneously occurs in the adult brain. These cellular resources are specially active after demyelinating episodes in early phases of multiple sclerosis (MS). Indeed, oligodendrocyte precursor cells (OPCs) actively proliferate, migrate to and repopulate the lesioned areas. Ultimately, efficient remyelination is accomplished when new oligodendrocytes reinvest nude neuronal axons, restoring the normal properties of impulse conduction. As the disease progresses this fundamental process fails. Multiple causes seem to contribute to such transient decline, including the failure of OPCs to differentiate and enwrap the vulnerable neuronal axons. Regenerative medicine for MS has been mainly centered on the recruitment of endogenous self-repair mechanisms, or on transplantation approaches. The latter commonly involves grafting of neural precursor cells (NPCs) or neural stem cells (NSCs), with myelinogenic potential, in the injured areas. Both strategies require further understanding of the biology of oligodendrocyte differentiation and remyelination. Indeed, the success of transplantation largely depends on the pre-commitment of transplanted NPCs or NSCs into oligodendroglial cell type, while the endogenous differentiation of OPCs needs to be boosted in chronic stages of the disease. Thus, much effort has been focused on finding molecular targets that drive oligodendrocytes commitment and development. The present review explores several aspects of remyelination that must be considered in the design of a cell-based therapy for MS, and explores more deeply the challenge of fostering oligodendrogenesis. In this regard, we discuss herein a tool developed in our research group useful to search novel oligodendrogenic factors and to study oligodendrocyte differentiation in a time- and cost-saving manner. 相似文献
5.
Sebastian Kallus Bernhard Englinger Julia Senkiv Anna Laemmerer Petra Heffeter Walter Berger Christian R. Kowol Bernhard K. Keppler 《Nanomedicine : nanotechnology, biology, and medicine》2018,14(8):2632-2643
Fibroblast growth factor receptor (FGFR) inhibitors like ponatinib and nintedanib are clinically approved for defined cancer patient cohorts but often exert dose-limiting adverse effects. Hence, we encapsulated the FGFR inhibitors ponatinib, PD173074, and nintedanib into polylactic acid nanoparticles and liposomes to enable increased tumor accumulation/specificity and reduce side effects. Different methods of drug loading were tested and the resulting formulations compared regarding average size distribution as well as encapsulation efficiency. Appropriate encapsulation levels were achieved for liposomal preparations only. Nanoencapsulation resulted in significantly decelerated uptake kinetics in vitro with clearly decreased short-term (up to 72?h) cytotoxicity at higher concentrations. However, in long-term clonogenic assays liposomal formations were equally or even more active as compared to the free drugs. Accordingly, in an FGFR inhibitor-sensitive murine osteosarcoma transplantation model (K7M2), only liposomal but not free ponatinib resulted in significant tumor growth inhibition (by 60.4%) at markedly reduced side effects. 相似文献
6.
目的 通过谷胱甘肽转硫酶偶联的血小板衍生因子受体氮端的融合蛋白(GST-PDGFR-N)制备有生物活性的单克隆抗体.方法 用GST-PDGFR-N融合蛋白作为免疫原,通过杂交瘤技术制备抗PDGFR的单克隆抗体,用间接ELISA、Western blot、免疫组化等方法对抗体的抗原结合特性进行鉴定.结果 获得两株能稳定分泌抗PDGFR单克隆抗体的细胞3B12F5和3C6H7C11,亚类鉴定两种单抗均为IgG1.间接ELISA法测定两株细胞腹水抗体的效价分别为1:102400为和1:25600.Western blot法显示PDGFR单克隆抗体特异性地识别免疫原和胶质瘤细胞株U251中的抗原成分.细胞免疫组化显示此单抗可以特异的识别胶质瘤细胞株U251和膀胱癌细胞株BIU87中表达的PDGFR抗原.结论 成功制备PDGFR单克隆抗体,为研究PDGFR的表达情况和临床检测提供了一个有用的工具. 相似文献
7.
《Expert opinion on emerging drugs》2013,18(4):845-854
This paper focuses on the medical management of malignant gliomas, which is currently undergoing change. It suggests that as surgery and radiotherapy are of limited benefit in the treatment of these tumours, medical therapies may have the potential to offer a better alternative. The current therapies for glioma and the targeted agents in clinical trials are reviewed. There is a general acceptance that temozolomide in combination with radiotherapy is replacing radiotherapy alone as first-line therapy in high-grade astrocytic gliomas. Within the realms of clinical research, it can be seen that there is a shift away from therapies targeting the end effect of deregulated cell-cycle control, to targeting specific and individual genetic aberrations in tumours. Finally, the paper questions current clinical trial methodology and tentatively suggests ways in which this may be improved. 相似文献
8.
BACKGROUND: There is a lack of effective treatment for metastatic adenoid cystic carcinoma (ACC), a usually indolent tumor. We studied the efficacy of imatinib mesylate, a potent inhibitor of KIT tyrosine kinase, in patients with KIT-positive metastatic ACC. METHOD: Five patients with lung metastasis were treated in a pilot study with imatinib 400 mg by mouth twice a day. Mutations of c-kit and platelet-derived growth factor receptor (PDGFR)-alpha in tumors from these patients were analyzed. RESULTS: Disease progression was noted in three of five patients during the short treatment periods, ranging from 2 to 3 weeks. Three patients died of disease within 6 months. No detectable mutations were found in c-kit and PDGFR-alpha. CONCLUSION: We observed an unexpected high progression rate of metastatic ACC within short periods during imatinib treatment. Use of imatinib to treat cancers without c-kit or PDGFR-alpha mutation should be approached with caution. 相似文献
9.
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the GI tract. Most of them are thought to be sporadic, but some arise in the settings of neurofibromatosis type I (NF-1) and the Carney triad. The Carney triad is a syndrome of unknown etiology, occurring predominantly in young females, comprising gastrointestinal stromal tumors, pulmonary chondromas, and extra-adrenal paragangliomas. GISTs of the Carney triad involve predominantly the body and the antrum of the stomach, are generally multifocal, and have a better prognosis than sporadic GISTs. We describe the clinical and pathological features of a case of Carney triad that featured multiple gastric GISTs, mediastinal paraganglioma, and esophageal leiomyoma. Ten years after gastric resection, the patient developed liver and peritoneal metastasis and was treated with Imatinib mesylate for 6 months with no change in the lesions. The molecular analysis of the GIST, the first reported in a gastric tumor from the triad, showed a wild-type KIT and PDGFRA genes. 相似文献
10.
Katayama R Huelsmeyer MK Marr AK Kurzman ID Thamm DH Vail DM 《Cancer chemotherapy and pharmacology》2004,54(1):25-33
Feline vaccine-associated sarcoma (VAS) is a biologically aggressive soft-tissue sarcoma that can develop at sites where inactivated feline vaccines have been administered. We showed that platelet-derived growth factor (PDGF) and its receptor (PDGFR) play a role in the growth of VAS cells. The presence of PDGFR- was confirmed in each of five VAS cell lines evaluated, one non-vaccine-associated feline fibrosarcoma (FSA) cell line and a feline fibroblast-derived cell line. The PDGF/PDGFR signaling pathway was inhibited in the VAS cell lines and the FSA cell line using the tyrosine kinase inhibitor imatinib mesylate (formerly called STI-571). Imatinib inhibited PDGF-BB-induced autophosphorylation of PDGFR in VAS cells and feline FSA cells in vitro in a dose-dependent manner. Imatinib also significantly inhibited growth of feline VAS tumors in a murine xenograft model. Imatinib reversed the protective effect of PDGF-BB on growth inhibition by doxorubicin and carboplatin. PDGF-BB protected VAS cells from serum starvation and doxorubicin-induced apoptosis but not carboplatin-induced apoptosis, and imatinib eliminated this protection. These observations suggest that imatinib inhibits PDGFR tyrosine kinase activity in feline soft tissue sarcomas in vitro and inhibits tumor growth in a xenograft model.Abbreviations C/10 Complete minimal essential medium supplemented with 10% FBS - CPT Carboplatin - DOX Doxorubicin - EGF Epidermal growth factor - FBS Fetal bovine serum - FSA Fibrosarcoma - HGF Hepatocyte growth factor - IGF-1 Insulin-like growth factor-1 - MTS 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium - PDGF Platelet-derived growth factor - PDGFR Platelet-derived growth factor receptor - PI Propidium iodide - VAS Vaccine-associated sarcomaThis work was supported in part by the American Veterinary Medical Association Feline Sarcoma Task Force. Imatinib mesylate was provided by Novartis Pharmaceuticals, Inc. 相似文献